PMID- 23190520
OWN - NLM
STAT- MEDLINE
DCOM- 20130510
LR  - 20151119
IS  - 1744-9987 (Electronic)
IS  - 1744-9979 (Linking)
VI  - 16
IP  - 6
DP  - 2012 Dec
TI  - High prevalence of anti-apolipoprotein/A-1 autoantibodies in maintenance 
      hemodialysis and association with dialysis vintage.
PG  - 588-94
LID - 10.1111/j.1744-9987.2012.01102.x [doi]
AB  - Autoantibodies to apolipoprotein/A-1 (anti-ApoA-1 IgG) have pro-atherogenic 
      properties in patients at high cardiovascular risk, but its prevalence in 
      patients with end-stage kidney disease is unknown. The aims of this 
      single-center, cross-sectional study were to assess the prevalence of anti-ApoA-1 
      antibodies in patients on maintenance hemodialysis (MHD), and to examine its 
      correlation with inflammatory biomarkers related to atherosclerotic plaque 
      vulnerability and dialysis vintage. To this purpose, anti-ApoA-1 IgG levels and 
      the concentrations of interleukin-6 (IL-6), interleukin-8 (IL-8), monocyte 
      chemoattractant protein-1 (MCP-1), metalloproteinase-9 (MMP-9), tumor necrosis 
      factor-alpha, and C-reactive protein (CRP) were assessed in the sera of 66 MHD 
      patients (mean age: 68 +/- 14 years, 36% women, 32% diabetics). Anti-ApoA-1 IgG 
      positivity (defined as a blood value >/= 97.5(th) percentile of the normal 
      distribution as assessed in healthy blood donors) was 20%. Circulating levels of 
      anti-ApoA-1 IgG correlated positively with dialysis vintage, but not with 
      cardiovascular risk factors or previous cardiovascular events; no significant 
      correlations were found between the anti-ApoA1 IgG levels and circulating levels 
      of IL-6, IL-8, MCP-1, MMP-9, CRP, or low-density lipoprotein-cholesterol. In 
      multivariable linear regression, adjusted for age and sex, only dialysis vintage 
      remained positively and independently associated with anti-ApoA-1 titers (beta = 
      0.05, 95% CI: 0.006; 0.28, P = 0.049). In conclusion, the prevalence of 
      anti-ApoA-1 IgG is raised in the MHD-population, and positively associated with 
      dialysis vintage, a major determinant of cardiovascular outcome. Whether 
      antiApoA-1 antibodies play a role in the pathophysiology of accelerated 
      atherosclerosis in the MHD-population merits further study.
CI  - (c) 2012 The Authors. Therapeutic Apheresis and Dialysis (c) 2012 International 
      Society for Apheresis.
FAU - Pruijm, Menno
AU  - Pruijm M
AD  - Division of Nephrology and Hypertension, Department of Internal Medicine, 
      University Hospital Lausanne, Lausanne, Switzerland. mennopruijm@hotmail.com
FAU - Schmidtko, Jan
AU  - Schmidtko J
FAU - Aho, Anthony
AU  - Aho A
FAU - Pagano, Sabrina
AU  - Pagano S
FAU - Roux-Lombard, Pascale
AU  - Roux-Lombard P
FAU - Teta, Daniel
AU  - Teta D
FAU - Burnier, Michel
AU  - Burnier M
FAU - Vuilleumier, Nicolas
AU  - Vuilleumier N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120912
PL  - Australia
TA  - Ther Apher Dial
JT  - Therapeutic apheresis and dialysis : official peer-reviewed journal of the 
      International Society for Apheresis, the Japanese Society for Apheresis, the 
      Japanese Society for Dialysis Therapy
JID - 101181252
RN  - 0 (Apolipoprotein A-I)
RN  - 0 (Autoantibodies)
RN  - 0 (Biomarkers)
RN  - 0 (Immunoglobulin G)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Apolipoprotein A-I/*immunology
MH  - Atherosclerosis/immunology/*physiopathology
MH  - Autoantibodies/*immunology
MH  - Biomarkers/metabolism
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/immunology
MH  - Inflammation/immunology
MH  - Kidney Failure, Chronic/therapy
MH  - Linear Models
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Plaque, Atherosclerotic/immunology
MH  - Prevalence
MH  - *Renal Dialysis
MH  - Risk Factors
MH  - Time Factors
EDAT- 2012/11/30 06:00
MHDA- 2013/05/11 06:00
CRDT- 2012/11/30 06:00
PHST- 2012/11/30 06:00 [entrez]
PHST- 2012/11/30 06:00 [pubmed]
PHST- 2013/05/11 06:00 [medline]
AID - 10.1111/j.1744-9987.2012.01102.x [doi]
PST - ppublish
SO  - Ther Apher Dial. 2012 Dec;16(6):588-94. doi: 10.1111/j.1744-9987.2012.01102.x. 
      Epub 2012 Sep 12.